Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV
Aug 01, 2024 13:34
Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus (RSV) in infants and children up to 24 months.
New Delhi, Aug 1 (PTI) Sanofi India on Thursday said it has received marketing authorisation approval from the Central Drugs Standard Control Organisation (CDSCO) for Beyfortus in India.
Beyfortus is used for the prevention of Respiratory Syncytial Virus (RSV) and Lower Respiratory Tract Disease (LRTD) in newborns and infants.
It is also administered to children up to 24 months of age, who remain vulnerable to severe RSV disease through their second RSV season.
RSV is a highly contagious virus that can lead to serious respiratory illness in infants.
"Prevention of RSV in India is still an unmet medical need. This makes the approval of Beyfortus a landmark moment for Sanofi in India," Sanofi Vaccines (India) General Manager Preeti Futnani stated.
In March 2017, Sanofi and AstraZeneca announced an agreement to develop and commercialise Beyfortus.
Under the terms of the agreement, AstraZeneca leads development and manufacturing activities, and Sanofi leads commercialisation activities and records revenues.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.